[Remote] Sr Marketing Manager, Signatera GI Oncology at Natera

United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Diagnostics, Biotech, Pharmaceuticals, OncologyIndustries

Requirements

Candidates must possess a Bachelor's degree in life sciences or a related field, with an advanced degree (MBA, PhD) being preferred. A minimum of 5-7 years of experience in product marketing, field sales, or market analytics within the diagnostics, biotech, or pharmaceutical industries is required. Experience in oncology and/or genomics is highly preferred, and familiarity with FDA-approved treatments and the clinical landscape in GI cancers is a strong plus. The role requires strategic thinking, strong business acumen, effective collaboration skills, customer orientation, excellent communication and organizational skills, and demonstrated success in managing key opinion leader relationships and external partnerships.

Responsibilities

The Senior Marketing Manager will develop and execute strategic and tactical marketing plans to drive the growth of Signatera in GI cancers and other solid tumors. This includes tracking and analyzing product performance metrics, leading the development of marketing collateral, and ensuring all digital content aligns with scientific evidence and messaging. The manager will also identify, engage, and manage partnerships with third-party organizations and collaborate cross-functionally with medical affairs, sales, digital, regulatory, legal, and external vendors to execute marketing initiatives. A significant portion of the role involves travel, estimated at 30%.

Skills

marketing strategy

product marketing

field sales

market analytics

oncology

genomics

GI cancers

digital marketing

content development

strategic planning

business acumen

collaboration

Natera

Genetic testing and diagnostics solutions provider

About Natera

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care and health outcomes through accurate genetic testing.

Austin, TexasHeadquarters

2004Year Founded

$149.9MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

1,001-5,000Employees

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Risks

Hindenburg report accuses Natera of deceptive sales practices, risking legal challenges.

New Prospera Heart features may face slow adoption by healthcare providers.

Fetal RhD NIPT demand may drop post-RhIg shortage, affecting future sales.

Differentiation

Natera's Signatera test offers personalized ctDNA analysis for cancer patients.

Prospera Heart test uses unique Donor Quantity Score for transplant rejection detection.

Panorama NIPT test is a leader in non-invasive prenatal testing with 2 million tests.

Upsides

Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.

AI integration enhances accuracy and speed of Natera's cfDNA analysis.

Growing personalized medicine trend aligns with Natera's customized genetic tests.

Land your dream remote job 3x faster with AI

Try Jobo Free